BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Trevena, Inc. to Present Results of TRV027 Phase 2a Study in Patients With Advanced Heart Failure


3/8/2013 8:50:38 AM

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that David Soergel, M.D., SVP of Clinical Development, will present the results of a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction, as a poster at the American College of Cardiology meeting, to be held in San Francisco on March 9th through 11th, 2013. The poster will be presented on Sunday, March 10th. Trevena successfully completed the Phase 2a study in October 2012, in which TRV027 was generally well-tolerated and produced a beneficial set of hemodynamic effects. Trevena is developing TRV027 for the intravenous hospital treatment of acute decompensated heart failure (ADHF), and the data being presented supports the advancement of TRV027 into further studies. A Phase 2b study to evaluate its clinical efficacy in patients with ADHF is currently being planned.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->